BIO Lawsuit Challenges CMS Authority Over GLOBE International Drug Pricing Pilot

{"The complaint asserts that the Centers for Medicare and Medicaid Services lacks statutory authority under the Social Security Act to implement a mandatory international reference pricing model through the Center for Medicare and Medicaid Innovation. Plaintiffs argue the pilot exceeds CMMI’s demonstration powers because it alters payment methodology without explicit congressional authorization and bypasses notice-and-comment rulemaking.","International reference pricing has shown mixed results in peer nations; Canadian and German systems achieve 20-40% lower launch prices but face documented launch delays averaging 12-18 months for new oncology agents. U.S. data from the 2020 Most Favored Nation interim final rule, later withdrawn, projected $64 billion in Medicare savings over seven years while raising concerns about reduced manufacturer investment in rare-disease indications.","The legal challenge raises ethical questions about balancing immediate affordability gains against long-term innovation incentives. Tying U.S. prices to smaller reference markets risks free-riding on foreign price controls, potentially shifting R&D costs onto non-U.S. payers or slowing development of therapies with modest domestic markets. The suit also tests whether CMMI can create de facto price controls without legislative change.","Next steps include a scheduled hearing on the preliminary injunction in early 2027. If granted, the pilot would be paused pending full merits review; a denial would allow the model to proceed while litigation continues, likely prompting additional industry challenges and possible congressional intervention before the 2028 election cycle."}